Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

NCT06496048 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Small Cell Lung Cancer

Interventions

DRUG: Lurbinectedin
DRUG: Irinotecan
DRUG: Lurbinectedin
DRUG: Topotecan

Sponsor

Luye Pharma Group Ltd.